We are studying whether adding short-term hormone therapy to a targeted treatment helps men with recurrent prostate cancer and a limited number of metastases live longer and improve their quality of life.
Health conditions and diseases that the clinical trial is designed to study and treat.
Oligorecurrent hormone-sensitive prostate cancer is a type of prostate cancer that has returned after initial treatment but is still responsive to hormone therapy. It typically involves a limited number of cancerous sites and may require targeted treatment.
These questions help us understand your situation so we can let the trial team know whether you might be a potential match. This is not a medical evaluation and is not part of the official screening, the study doctor will make the final decision..
Don't worry if you don't know the medicines tested in the trial. There is a chance you have heard about the similar medicines. Check the list below to see if you are familiar with any of them.
Locations and medical facilities where this clinical trial is currently recruiting or conducting research. Select the locations where you would like to participate.
Disclaimer: Parts of this content have been automatically extracted from the EU Clinical Trials registry. While we strive for accuracy, please always contact the trial site or sponsor directly for correct and official information before making any decisions about participation. View on EU Clinical Trials.